健康专业人员随访研究中阿司匹林使用与致死性前列腺癌的关系
该研究基于健康专业人员随访研究,纳入49409名男性进行风险分析、5980例非转移性前列腺癌患者进行生存分析,采用Cox比例风险回归模型评估定期服用阿司匹林与致死性前列腺癌的关联。结果显示,当前定期服用阿司匹林与致死性前列腺癌风险降低相关(HR 0.80,95%CI 0.66-0.96),诊断后服用与致死性前列腺癌风险降低(HR 0.80,95%CI 0.64-1.00)及全因死亡风险降低(HR 0.79,95%CI 0.69-0.90)相关。
要点
- 当前定期服用阿司匹林与致死性前列腺癌风险降低相关(HR 0.80,95%CI 0.66-0.96)。
- 诊断后当前服用阿司匹林与致死性前列腺癌风险降低相关(HR 0.80,95%CI 0.64-1.00)。
- 诊断后当前服用阿司匹林与全因死亡风险降低相关(HR 0.79,95%CI 0.69-0.90)。
核心结论
- 定期服用阿司匹林与致死性前列腺癌风险降低相关。
- 诊断后服用阿司匹林与诊断后生存改善相关。
研究设计与样本
- 研究基于健康专业人员随访研究,基线为1986年、年龄40-75岁的男性,每两年一次问卷随访。
- 风险分析纳入49409名男性,生存分析纳入5980例诊断时无转移的前列腺癌患者。
- 采用Cox比例风险回归模型分析当前、既往或从不定期服用阿司匹林(≥2天/周)与致死性(转移或致命)前列腺癌的关联。
主要发现
- 基线时29%的参与者定期服用阿司匹林,至2010年增至60%。
- 风险分析中804名男性被诊断为致死性前列腺癌,当前定期服用阿司匹林者较从不服用者致死性前列腺癌风险降低(HR 0.80,95%CI 0.66-0.96)。
- 生存分析中451例非转移性前列腺癌患者 later 发展为致死性疾病,诊断后当前服用阿司匹林与致死性前列腺癌风险降低相关(HR 0.80,95%CI 0.64-1.00),与全因死亡风险降低相关(HR 0.79,95%CI 0.69-0.90)。
- 在高度筛查的男性中,风险分析的关联更强,生存分析的关联仍具统计学显著性。
临床怎么用
- 作者在患者摘要中认为,前列腺癌患者服用阿司匹林以改善前列腺癌死亡和其他死亡结局可能是可取的。
局限性
- 反向因果和残余混杂仍是担忧,敏感性分析中结果减弱证明了这一点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin use probably protects against some malignancies but its effects on lethal prostate cancer (PC) are unclear. OBJECTIVE: To investigate the association between regular aspirin use and lethal PC. DESIGN, SETTING, AND PARTICIPANTS: Participants were aged 40-75 yr at baseline in 1986 and have been followed with biennial questionnaires. The risk analysis includes 49 409 men. The survival analysis includes 5980 PC patients without metastatic disease at diagnosis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used Cox proportional hazards regression to examine the association between current, past, or never regular aspirin use (≥2 d/wk) in relation to lethal (metastatic or fatal) PC. We also examined years of use among current users and years since stopping among past users. In the risk analysis, aspirin was updated throughout follow-up. In the survival analysis, aspirin use after diagnosis was assessed. RESULTS AND LIMITATIONS: Some 29% of participants used aspirin regularly at baseline, which increased to 60% by 2010. In the risk analysis, 804 men were diagnosed with lethal PC. Current regular aspirin was associated with a lower risk of lethal prostate cancer (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.66-0.96) compared to never users. In the survival analysis, 451 of the men diagnosed with nonmetastatic PC later developed lethal disease. Current postdiagnostic aspirin was associated with a lower risk of lethal PC (HR 0.80, 95% CI 0.64-1.00) and overall mortality (HR 0.79, 95% CI 0.69-0.90). When restricted to highly screened men, the risk analysis associations were stronger and survival analysis associations remained statistically significant. Reverse causation and residual confounding remain concerns, as demonstrated by the attenuated results in sensitivity analyses. CONCLUSIONS: Regular aspirin use was associated with a lower risk of lethal PC. Postdiagnostic use was associated with better survival after diagnosis. PATIENT SUMMARY: We found that it may be advisable for prostate cancer patients to take aspirin to improve their survival for both prostate cancer mortality and other mortality outcomes.
引用
- Downer MK, Allard CB, Preston MA, et al. Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. Eur Urol Oncol. 2018. PMID: 31017087. doi:10.1016/j.euo.2018.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。